Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646894 | 0.86 | CTSA (0.42) | HTR7FFAR1CASRCTSA | |
| SCHEMBL1759316 | 0.80 | PTGER1 (0.49) | HTR7FFAR1CASRCTSABCHE | |
| SCHEMBL12726016 | 0.79 | SGMS2 (0.39) | FFAR1BCHEPTGER1PTGER4PTGER3 | |
| SCHEMBL1759131 | 0.79 | MGAM (0.47) | FFAR1BCHEMGAMGAASI | |
| SCHEMBL1638059 | 0.79 | MGAM (0.47) | FFAR1BCHEMGAMGAASI | |
| SCHEMBL12725985 | 0.78 | BCHE (0.57) | BCHEMGAMGAASIMGAM2 | |
| SCHEMBL1759387 | 0.77 | FFAR1 (0.47) | HTR7FFAR1BCHEMGAMGAA | |
| SCHEMBL1758876 | 0.77 | BCHE (0.46) | BCHEMGAMGAASIMGAM2 | |
| SCHEMBL12646976 | 0.74 | SMN1; SMN2 (0.41) | CTSA | |
| SCHEMBL1641884 | 0.74 | SGMS2 (0.53) | HTR7BCHEMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2493932-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056423-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | ALOX12, THEM6, ALOX15 | HTR7 3223/4885FFAR1 480/4885CASR 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.